BioSpace News Archive

Royal Philips, a global leader in health technology, announced that the company earned a spot on Forbes’ 2023 “America’s Best Employers for Women” list.

Today, The Feinstein Institutes for Medical Research at Northwell Health announced the publication of the results from the SKYLARK Study, a phase 3 placebo-controlled clinical trial of an investigational oral, 14-day neuroactive steroid zuranolone (50mg) pill in the treatment of PPD.

Harbinger Health (“Harbinger,” “the Company”), a biotechnology company pioneering the detection of early cancer, today announced data demonstrating the development and advancement of its biology and machine-learning-driven platform, HarbingerHx.

Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced that the Company has submitted its first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with intranasally administered scopolamine gel (DPI-386 Nasal Gel) for prevention of nausea and vomiting induced by motion in adults.

Median Technologies, announces the publication date for its 2023 half year results and its Q3, 2023 business performance.

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that eClinicalMedicine has published clinical data on MaaT013 as a treatment for acute Graft-versus-Host Disease (aGvHD).

Akoya Biosciences, Inc., The Spatial Biology Company®, announced that Company management will be participating in three upcoming investor conferences.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced Company management will participate in the following investor conferences:

Verrica Pharmaceuticals Inc. announced the closing of the previously announced $125 million debt financing with OrbiMed, a leading healthcare investment firm.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the 43rd Annual Canaccord Growth Conference on Wednesday, August 9, 2023 at 4:00 p.m. Eastern Time at the InterContinental Boston Hotel in Boston, MA.